PEG-IFN-α-2a therapy in patients with myelofibrosis

被引：47
|
作者：
Ianotto, Jean-Christophe [1 ]
Kiladjian, Jean-Jacques [2 ]
Demory, Jean-Louis [3 ]
Roy, Lydia [4 ]
Boyer, Francoise [5 ]
Rey, Jerome [6 ]
Dupriez, Brigitte [7 ]
Berthou, Christian [1 ]
Abgrall, Jean-Francois [8 ]
机构：
[1] Hop Morvan, CHU, Inst Canc Hematol, Serv Hematol Clin, Brest, France
[2] AP HP, Serv Hematol Clin, Bobigny, France
[3] Hop St Vincent, Dept Hematol, Lille, France
[4] CHU La Miletrie, Dept Oncohematol & Therapie Cellulaire, Poitiers, France
[5] CHU Angers, Serv Malad Sang, Angers, France
[6] Inst J Paoli I Calmettes, Dept Oncohematol, F-13009 Marseille, France
[7] CH, Serv Hematol Clin, Lens, France
[8] CHU Brest, Hop Cavale Blanche, Hematol Lab, F-29285 Brest, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 146卷 / 02期
关键词：
myelofibrosis; treatment; pegylated-interferon; response criteria; European Myelofibrosis Network; MYELOID METAPLASIA; POLYCYTHEMIA-VERA; INTERFERON; CRITERIA;
D O I：
10.1111/j.1365-2141.2009.07745.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：223 / 225
页数：3
相关论文
共 50 条
  • [1] A novel PEG-IFN-α2a in chronic HCV genotype 4 patients
    Gamal, Esmat
    Goubran, Hadi
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2007, 27 (08): : 709 - 709
  • [2] Comparison of a 24-week standard combination therapy with PEG-IFN-α2a/ribavirin with a 12-week monotherapy with PEG-IFN-α2a followed by a 12 week standard combination with PEG-IFNα2a/ribavirin in hepatitis C infected patients with genotype 2 or 3
    Kallinowski, Birgit
    Stein, Kerstin
    Böcher, Wulf
    Tobias, Goeser
    Spengler, Ulrich
    Link, Ralph
    Klinker, Hartwig
    Bruckner, Tom
    Haiss, Peter
    Buggisch, Peter
    HEPATOLOGY, 2006, 44 (04) : 612A - 612A
  • [3] Preclinical selection and clinical evaluation of pegylated recombinant interferon α2a (PEG-IFN-α2a)
    Brunda, MJ
    Aglione, A
    Ballon, P
    Dvorozniak, M
    Graves, M
    Keith, D
    Palleroni, A
    Truitt, G
    Hoffman, J
    Xu, ZX
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 400 - 400
  • [4] The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-IFN-α 2a in HBeAgpositive CHB Patients
    Yong-jian Ji
    Wan-hua Ren
    Fei-fei Li
    Jian-ting Fang
    Xi-zhen Sun
    Cheng-yong Qin
    InfectionInternational(ElectronicEdition), 2013, 2 (03) : 127 - 131
  • [5] Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
    Dahari, Harel
    Affonso de Araujo, Evaldo S.
    Haagmans, Bart L.
    Layden, Thomas J.
    Cotler, Scott J.
    Barone, Antonio A.
    Neumann, Avidan U.
    JOURNAL OF HEPATOLOGY, 2010, 53 (03) : 460 - 467
  • [6] PLASMA BIOMARKERS PREDICT RESPONSE TO PEG-IFN-α2/RIBAVIRIN THERAPY
    Mallet, Vincent
    Renard, Philippe
    Denis, Jacques
    Vallet-Pichard, Anais
    Casrouge, Armando
    Hezode, Christophe
    Rosa, Isabelle
    Hagege, Herve
    Pawlotsky, Jean-Michel
    Mapes, James
    Albert, Matthew L.
    Pol, Stanislas
    HEPATOLOGY, 2010, 52 (04) : 1238A - 1238A
  • [7] Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients
    Alvandi, Zahra
    Provacia, Lisette
    Martina, Byron E. E.
    Osterhaus, Albert D. M. E.
    Haagmans, Bart L.
    CYTOKINE, 2009, 48 (1-2) : 92 - 92
  • [8] Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythernia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy
    Quintas-Cardama, Alfonso
    Abdel-Wahab, Omar
    Levine, Ross L.
    Manshouri, Taghi
    Roupie, Anne-Laure
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2011, 118 (21) : 130 - 130
  • [9] Pharmacodynamics of PEG-IFN-α-2a and HCV Response as a Function of IL28B Polymorphism in HIV/HCV-Coinfected Patients
    Affonso de Araujo, Evaldo Stanislau
    Dahari, Harel
    Cotler, Scott J.
    Layden, Thomas J.
    Neumann, Avidan U.
    Melo, Carlos Eduardo
    Barone, Antonio Alci
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (02) : 95 - 99
  • [10] Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)
    Quintas-Cardania, Alfonso
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Richie, Marie Ann
    Borthakur, Gautam
    Verstovsek, Srdan
    BLOOD, 2008, 112 (11) : 246 - 246
12345